论文部分内容阅读
作者应用重组组织纤维蛋白溶酶原活化因子(t-PA),对3例急性肺血栓栓塞症(PTE)行血栓溶解治疗,测定用药前后血中纤维蛋白溶酶-α_2、纤维蛋白溶酶抑制剂复合物(PIC)和纤维蛋白降解产物二聚体(FDP-D),研究这些指标与治疗的实际意义。急性PTE 确诊后,首次予以肝素5,000u 静脉内给药,以后250～300u/kg/日持续用药。经行肺动脉造影检查和肺血流闪烁扫描后给予t-PA 治疗。将t-PA1,500万单位溶于生理盐水100ml中静滴,每日一次,每次1小时内输入,连续治疗3天。使用t-PA 前后和用药7天后采血作分子标记物测定,并作疗效判定。
The authors applied recombinant tissue plasminogen activator (t-PA) to thrombolysis in 3 patients with acute pulmonary thromboembolism (PTE), and measured the changes of serum plasmin-α 2 and plasmin before and after treatment (PIC) and fibrin degradation product dimer (FDP-D), the actual significance of these indicators and treatment. After the diagnosis of acute PTE, heparin 5000u intravenous administration for the first time, after 250 ~ 300u / kg / day continuous medication. T-PA was given after pulmonary angiography and pulmonary blood flow scintigraphy. The t-PA15 million units dissolved in saline 100ml intravenously once a day, each input within 1 hour, continuous treatment for 3 days. Before and after the use of t-PA and 7 days after drug use for molecular markers of blood collection, and for efficacy determination.